Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease

Neurology

Volumn 65, Issue 3, 2005, Pages 383-390

  Popat, Rita A ^a   Van Den Eeden, S K ^b   Tanner, C M ^c   McGuire, V ^a   Bernstein, A L ^d   Bloch, D A ^a   Leimpeter, A ^b   Nelson, L M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c PARKINSON S INSTITUTE   (United States)

^d Kaiser Santa Rosa Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENARCHE; OVARIECTOMY; PARITY; PARKINSON DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; REPRODUCTION; RISK REDUCTION; SMOKING; UNITED STATES;

EID: 23244444082     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000171344.87802.94     Document Type: Article

References (29)

1. Van Den Eden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson' disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
2. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000;55:1358-1363.
3. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142:820-827.
4. Van Hartesveldt C, Joyce JN. Effects of estrogen on the basal ganglia. Neurosci Biobehav Rev 1986;10:1-14.
5. Kompoliti K. Estrogen and movement disorders. Clin Neuropharmacol 1999;22:318-326.
6. Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J Neurochem 1995;65:1651-1657.
7. Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 1999;56:31-38.
8. Disshon KA, Boja JW, Dluzen DE. Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur J Pharmacol 1998;345:207-211.
9. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001;16:830-837.
10. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004;62:2010-2014.
11. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Post-menopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004;61:886-888.
12. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998;50:1141-1143.
13. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003;60:790-795.
14. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
15. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
16. Hosmer Jr, DW Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
17. McKinlay SM. Issues in design, measurement, and analysis for menopause research. Exp Gerontol 1994;29:479-493.
18. Derby CA, Hume AL, Barbour MM, McPhillips JB, Lasater TM, Carleton RA. Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol 1993;137:1125-1135.
19. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-1220.
20. Di Paolo T, Rouillard C, Bedard P. 17 beta-estradiol at a physiological dose acutely increases dopamine turnover in rat brain. Eur J Pharmacol 1985;117:197-203.
21. Hruska RE, Silbergeld EK. Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model. Science 1980;208:1466-1468.
22. Roy EJ, Buyer DR, Licari VA. Estradiol in the striatum: effects on behavior and dopamine receptors but no evidence for membrane steroid receptors. Brain Res Bull 1990;25:221-7.
23. Disshon KA, Dluzen DE. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release. Brain Res 1997;764:9-16.
24. Levesque D, Di Paolo T. Rapid conversion of high into low striatal D2-dopamine receptor agonist binding states after an acute physiological dose of 17 beta-estradiol. Neurosci Lett 1988;88:113-118.
25. Dupont A, Di Paolo T, Gagne B, Barden N. Effects of chronic estrogen treatment on dopamine concentrations and turnover in discrete brain nuclei of ovariectomized rats. Neurosci Lett 1981;22:69-74.
26. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57B1/6 mice. Synapse 2001;41:131-138.
27. Dluzen DE, Ramirez VD. Intermittent infusion of progesterone potentiates whereas continuous infusion reduces amphetamine-stimulated dopamine release from ovariectomized estrogen-primed rat striatal fragments supervised in vitro. Brain Res 1987;406:1-9.
28. Fernandez-Ruiz JJ, de Miguel R, Hernandez ML, Ramos JA. Time-course of the effects of ovarian steroids on the activity of limbic and striatal dopaminergic neurons in female rat brain. Pharmacol Biochem Behav 1990;36:603-606.
29. Kalia V, Fenske C, Hole DR, Wilson CA. Effect of gonadal steroids and gamma-aminobutyric acid on LH release and dopamine expression and activity in the zona incerta in rats. J Reprod Fertil 1999;117:189-197.